Loading...

Invex Therapeutics Ltd

IXC.AX•ASX
Healthcare
Biotechnology
A$0.09
A$0.007(8.24%)

Invex Therapeutics Ltd (IXC.AX) Company Profile & Overview

Explore Invex Therapeutics Ltd’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Invex Therapeutics Ltd (IXC.AX) Company Profile & Overview

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.

SectorHealthcare
IndustryBiotechnology
CEONarelle Warren LLB

Contact Information

https://www.invextherapeutics.com
61 8 6382 0137
38 Rowland Street, Perth, WA, 6008

Company Facts

IPO DateJul 5, 2019
CountryAU
Actively Trading

Frequently Asked Questions

;